NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

SNDX

Syndax Pharmaceuticals, Inc. Common Stock Nasdaq Global Select
$15.27
Open: $15.33 High: $15.75 Low: $14.61 Close: $15.27
Range: 2021-05-06 - 2021-05-07
Volume: 442,677
Market: Closed
Powered by Finage Stock APIDelayed data
SNDX
Syndax Pharmaceuticals, Inc. Common Stock 35 Gatehouse Drive Waltham MA, 2451 http://www.syndax.com
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.
  • CEO: Briggs Morrison
  • Employees: 45
  • Sector: Healthcare
  • Industry: Biotechnology
SNDX News
Latest news about the SNDX
  • Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.

    View More →
  • Dennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On Shares

    Potential Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders may wish to note that the Independent Chairman...

    View More →
  • Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?

    Syndax (SNDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    View More →
  • Why Syndax Pharmaceuticals Stock Is Sinking Today

    Shares of Syndax Pharmaceuticals (NASDAQ: SNDX) were sinking 28% as of 11:32 a.m. EDT on Tuesday. This big decline came after the company reported positive results from a phase 1 study evaluating SNDX-5613 in treating leukemia. The company reported a 48% overall response rate in patients with mixed lineage leukemia-rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias.

    View More →
  • Syndax Lower as Blood Cancer Drug Trial Disappoints Investors

    The results of Syndax's Phase 1 trial of a blood-cancer-treatment candidate came up short of an investment firm's estimate.

    View More →
  • Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias. SNDX-5613 is the Company's highly selective, oral menin inhibitor. Information on how to access the live video webcast and accompanying slide presentation can be found below.

    View More →
  • Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20, 2021 at 8:00 a.m. ET. SNDX-5613 is the Company's highly selective, oral menin inhibitor.

    View More →
  • Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF

    The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.

    View More →
  • Syndax Pharma’s Axatilimab Receives Orphan Drug Designation For Treatment Of Chronic Lung Disease

    Clinical-stage biopharmaceutical company Syndax Pharmaceuticals, Inc. has received Orphan Drug Designation for axatilimab from the U.S. Food and Drug Administration (FDA) for treating patients with idiopathic pulmonary fibrosis (IPF). Axatilimab is a monoclonal antibody that targets CSF-1R, a cell surface protein. Syndax Pharmaceuticals (SNDX) Chief Executive Officer Briggs W. Morrison, M.D., said, “IPF is a serious, life-limiting orphan disease, and today’s Orphan Drug Designation validates axatilimab’s potential to serve as an effective therapeutic option for the currently-underserved patients living with this rare disease.” Morrison added, “Building on promising data demonstrating meaningful multiorgan clinical benefit in patients with chronic graft versus host disease, we are actively evaluating options to expand the axatilimab franchise into additional areas of high unmet need where the monocyte-macrophage lineage plays a key role in the fibrotic disease process.” (See Syndax Pharmaceuticals stock analysis on TipRanks) IPF is a chronic lung disease with a median survival of 3-5 years post-diagnosis. Present therapies on the market only slow the disease but do not stop its progression. The only curative therapy for IPF is a lung transplant. According to the company, IPF could affect about 150 thousand patients in the U.S. and 260 thousand patients across the 7 major pharmaceutical markets. On March 31, axatilimab also received orphan drug designation for the treatment of patients with chronic graft versus host disease (cGVHD). Last month, Stifel Nicolaus analyst Konstantinos Aprilakis reiterated a Buy rating on the stock with a $39 price target (71.1% upside potential). Aprilakis commented, “We expect the company to continue finding success with SNDX-5613, its lead asset and menin/MLL inhibitor for potential use in acute leukemias, and axatilimab, an anti-CSF-1R antibody currently being developed in cGVHD.” Consensus on the street is that Syndax Pharmaceuticals is a Strong Buy based on 3 unanimous Buys. The average analyst price target of $35.33 implies upside potential of 55%. Shares have gained about 149.3% over the past year. Related News: Best Buy Launches $200 Per Year Membership Program Okta Reaffirms Financial Outlook, Launches New Products On Investor Day Shell Expects To Take A $200M Hit From Texas Winter Storm More recent articles from Smarter Analyst: KemPharm Amends AZSTARYS Licensing Agreement With Gurnet Point Capital Affiliate Levi’s 1Q Sales And EPS Beat Estimates; Street Says Buy Crown Holdings To Sell 80% Of European Tinplate Business To KPS Capital For €1.9B Tyson Foods Officially Opens New $425M Tennessee Poultry Complex

    View More →
  • Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

    View More →
  • Is SNDX Stock A Buy or Sell?

    After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of December 31st. The results of that effort will be put on display in this article, as […]

    View More →
  • Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD

    The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.

    View More →
  • Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with chronic graft versus host disease (cGVHD).

    View More →
  • Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Debt In A Risky Way?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

    View More →
  • Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates

    Syndax Pharmaceuticals reported a better-than-expected loss in the fourth quarter and outpaced analysts’ expectations for revenues. Shares of the clinical-stage biopharmaceutical company dropped 1.2% to close at $23.30 on March 8. Syndax (SNDX) incurred a loss of $0.44 per share in 4Q, compared to the $0.49 loss per share estimated by analysts. Total revenue came in at $380,000, topping analysts’ expectations of $200,000. The company’s research and development expenses were $15.5 million in the quarter, up 63.2% year-over-year. Total operating expenses stood at $20.2 million, up 38.4%. (See Syndax stock analysis on TipRanks) Syndax CEO Briggs W. Morrison said, “We expect 2021 will be a year of immense progress across our two highly promising programs aimed at addressing key areas of unmet need, coupled with a sharp focus on pipeline expansion.” “Notably, we plan to present data from the Phase 1 portion of our ongoing AUGMENT-101 trial of SNDX-5613, our selective menin inhibitor, in patients with acute leukemias,” Morrison added. For 2021, the company projects research and development expenses to be in the range of $90 million to $100 million. Total operating expenses are anticipated to range from $110 million to $120 million. For 1Q, research and development expenses are forecasted to be in the range of $25 million to $30 million, with total operating expenses in the range of $30 to $35 million. Following the 4Q results, Stifel Nicolaus analyst Konstantinos Aprilakis maintained a Buy rating and a price target of $39 (67.4% upside potential) on the stock as the analyst is “enthusiastic about the menin space.” Aprilakis expects “the company to continue finding success with SNDX-5613, its lead asset and menin/MLL inhibitor for potential use in acute leukemias, and axatilimab, an anti-CSF-1R antibody currently being developed in cGVHD.” Syndax shares have exploded almost 108% over the past year, while the stock still scores a Strong Buy consensus rating based on 3 unanimous Buys. That’s alongside an average analyst price target of $35.33, which implies 51.6% upside potential to current levels. Additionally, Syndax scores an 8 out of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: Hibbett 4Q Profit Exceeds Estimates As E-commerce Sales Boom; Shares Tank 4% Big Lots’ 4Q Profit Beats Analysts’ Estimates As Comparable Sales Rise; Shares Gain 2% Cooper’s 1Q Results Beat The Street Consensus; Street Says Buy More recent articles from Smarter Analyst: McAfee To Divest Enterprise Business For $4B In Cash, Stock Gains 13% National Cinemedia Sinks 10% On Worse-Than-Feared 4Q Loss, Sales Plunge 89% Shift Technologies’ 1Q Sales Outlook Tops Estimates After 4Q Beat; Shares Pop 10% DuPont Inks $2.3B Deal To Snap Up Laird Performance Materials; Shares Gain

    View More →
  • Syndax Pharmaceuticals: Q4 Earnings Insights

    Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.44), which beat the estimate of ($0.49). Revenue of $380,000 unchanged by 0.00% from the same period last year, which beat the estimate of $200,000. Guidance Syndax Sees Q1 2021 R&D Expenses $25M-$30M; Sees Total Operating Expenses $30M-$35M Syndax Pharmaceuticals Sees FY 2021 R&D Expenses $90M-$100M; Sees FY 2021 Total Operating Expenses $110M-$120M Conference Call Details Date: Mar 08, 2021 Time: 04:30 PM View more earnings on SNDX ET Webcast URL: https://edge.media-server.com/mmc/p/wdaqmgg3 Recent Stock Performance 52-week high: $27.85 Company's 52-week low was at $6.88 Price action over last quarter: Up 22.96% Company Overview Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 8, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2020. In addition, the Company provided a clinical and business update.

    View More →
  • Syndax Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2021 / Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 8, 2021 at 4:30 PM Eastern Time.

    View More →
  • The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings

    Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA rulings and clinical readouts. Morphic Holding Inc (NASDAQ: MORF) was among the biggest gainers of the week after the company reported a positive early-stage readout in inflammatory bowel disease patients. M&A momentum continued, as Amgen Inc. (AMGN) announced a deal to buy Five Prime Therapeutics, Inc. (NASDAQ: FPRX) in an $1.9-billion all-cash deal. Here are the key catalysts for the unfolding week: Conferences Chardan's 3rd Annual Microbiome Medicines Summit: March 8 H.C. Wainwright Global Life Sciences Conference: March 9-11 Barclays Global Healthcare Conference: March 9-11 15th International Conference on Alzheimer's and Parkinson's disease: March 9-14 Clinical Readouts Prothena Corporation plc (NASDAQ: PRTA) will present at the Alzheimer's and Parkinson's disease conference new preclinical data on a treatment for Alzheimer's disease. The treatment targets an anti-tau antibody, which is thought to play a role in the disease. The company says targeting a certain antibody called a novel epitope with PRX005 has shown superior results. The presentation is scheduled for Thursday, March 11, between 7:30 a.m. and 7:45 a.m. Earnings Monday Minerva Neurosciences, Inc. (NASDAQ: NERV) (before the market open) Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) (after the close) Castle Biosciences, Inc. (NASDAQ: CSTL) (after the close) SI-BONE, Inc. (NASDAQ: SIBN) (after the close) Avadel Pharmaceuticals plc (NASDAQ: AVDL) (after the close) View more earnings on IBB Related Link: Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Tuesday Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (before the market open) Trevena, Inc. (NASDAQ: TRVN) (before the market open) InspireMD, Inc. (NYSE: NSPR) (before the market open) Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) (before the market open) DarioHealth Corp. (NASDAQ: DRIO) (before the market open) Gamida Cell Ltd. (NASDAQ: GMDA) (before the market open) Evelo Biosciences, Inc. (NASDAQ: EVLO) (before the market open) ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (before the market open) Aquestive Therapeutics, Inc. (NASDAQ: AQST) (after the close) Brickell Biotech, Inc. (NASDAQ: BBI) (after the close) Cytosorbents Corporation (NASDAQ: CTSO) (after the close) Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) (after the close) MiMedx Group, Inc. (NASDAQ: MDXG) (after the close) Inari Medical, Inc. (NASDAQ: NARI) (after the close) Lyra Therapeutics, Inc. (NASDAQ: LYRA) (after the close) Wednesday Bio-Path Holdings, Inc. (NASDAQ: BPTH) (before the market open) Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open) BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (before the market open) Clearside Biomedical, Inc. (NASDAQ: CLSD) (after the close) DiaMedica Therapeutics Inc. (NASDAQ: DMAC) (after the close) Five Prime Therapeutics (NASDAQ: FPRX) (after the close) Flexion Therapeutics, Inc. (NASDAQ: FLXN) (after the close) Harpoon Therapeutics, Inc. (NASDAQ: HARP) (after the close) Lantern Pharma Inc. (NASDAQ: LTRN) (after the close) TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (after the close) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (after the close) Protagonist Therapeutics, Inc. (NASDAQ: PTGX) (after the close) OrthoPediatrics Corp. (NASDAQ: KIDS) (after the close) Thursday Burning Rock Biotech Limited (NASDAQ: BNR) (before the market open) BioXcel Therapeutics, Inc. (NASDAQ: BTAI) (before the market open) Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open) Achieve Life Sciences, Inc. (NASDAQ: ACHV) (after the close) Capricor Therapeutics, Inc. (NASDAQ: CAPR) (after the close) Lineage Cell Therapeutics, Inc. (NYSE: LCTX) (after the close) Geron Corporation (NASDAQ: GERN) (after the close) Chembio Diagnostics, Inc. (NASDAQ: CEMI) (after the close) Ocular Therapeutix, Inc. (NASDAQ: OCUL) (after the close) Nabriva Therapeutics plc (NASDAQ: NBRV) (after the close) Related Link: Johnson & Johnson Secures Emergency Authorization For Its Single-Shot COVID-19 Vaccine See more from BenzingaClick here for options trades from BenzingaThe Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 StudyThe Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2020 financial results on Monday, March 8, after the close of the U.S. financial markets.

    View More →